Core Viewpoint - Changmao Biological (00954) has issued a profit warning, expecting a net loss of approximately RMB 24 million to 27 million for the six months ending June 30, 2025, compared to a net loss of approximately RMB 18.786 million for the same period ending June 30, 2024 [1] Financial Performance - The board of directors attributes the anticipated financial performance to several factors, including a decline in product sales prices and intense market competition, which have led to reduced sales revenue and gross profit [1] - Additionally, there has been an increase in interest expenses included in the consolidated income statement, primarily due to a decrease in the amount of capitalized interest expenses for qualifying assets [1]
常茂生物(00954)发盈警 预计中期净亏损约2400万至2700万元